Press Room


    Press Release - June 05, 2001

    Pheromone Sciences appoints Chief Financial Officer

    Pheromone Sciences Corp (CDNX:PHS), is pleased to announce the appointment of Mr. Larry Cooper C.A. as its Chief Financial Officer.

    A Chartered Accountant and member of the both the Order of Chartered Accountants and the Canadian Institute of Chartered Accountants, Mr. Cooper brings an enviable mix of financial and business development experience to the Company. Most recently, Mr. Cooper served as the Chief Financial Officer and Chief Administrative Officer of The Canadian Institute, an international business service provider with offices located in London, New York & Toronto.

    Prior thereto, he spent ten years (1988-1998) with Allergan Canada a multi-national pharmaceutical manufacturer of prescription and non- prescription healthcare products. During this timeframe Mr. Cooper spent the first six years as Chief Financial Officer and thereafter as both the Chief Financial Officer and the Director of Business Development

    Additional experience includes financial roles at Spalding Canada (1984--1988) where he was Chief Financial Officer, United Tire and Rubber Company (1982- -1984) and as the Accounting Manager at ENS Biologicals Inc. Mr. Cooper received his Bachelor of Commerce (Honors) degree from The University of Toronto.

    In commenting on the announcement, Mr. Neuman CEO said "Mr. Cooper's experience is ideally suited to the further development and implementation of Pheromone Sciences Corp's business strategy. We are delighted to have Larry join our team."

    Mr. Cooper succeeds Mr. Barry Sadrehashemi C.A., who has faithfully and efficiently served Pheromone Sciences from his Calgary base during the Company's transition to a public entity and subsequent move to Toronto.


    Lorne Woods 1-(800) 937-3095

    Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.

    Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The Canadian Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.


    Press Releases from:

    2018 2017 2016 2015 2014 2013 2012

    2011 2010 2009 2008 2007 2006 2005

    2004 2003 2002 2001 2000 1999

    Featured News

    2014, January 22

    Sernova’s Disruptive Regenerative Medicine Technologies Set to Improve the Treatment of Chronic Diseases While Reducing Healthcare Costs


    2012, July 11

    Sernova Corp. developing a tiered approach to the treatment of diabetes

    Publisher: Canadian Investor Magazine
    Author: Rochelle Emnance


    2012, July 30

    Feds back local diabetes discovery

    Publisher: London Free Press
    Author: Norman De Bono

    2012, July 30

    Federal program pumps $3 million into new, London business

    Publisher: The London Free Press

    Author: Norman De Bono

    2010 July 10

    Canada's economic action plan supports business innovators

    Publisher: Federal Economic Development Agency for Southern Ontario


    2007, February 20

    "Transplanted cells may protect against diabetes without forced drug use: An interview with Dr. David White"

    Author: Julie Ickes and James Finch

    2006, October 04

    "Sertoli Cells: Mother nature's anti-rejection drug"

    Author: James Finch

    2006, August 24

    "Mass marketing diabetes reversal; novel xeno-transplants may offer new hope for type 1 diabetics"

    Author: James Finch

    Presentation and Video

    May 03, 2018

    Corporate Presentation

    April 2018

    March 29, 2018

    2018 Financial Report - 1st Quarter

    March 29, 2018

    2018 Management Discussion & Analysis (MD&A) - 1st Quarter

    December 11, 2017

    Clearance by FDA of Sernova's US IND

    Conference call audio recording

    September 11, 2017

    Sernova Fact Sheet

    Subscribe to Sernova News